NEKTAR THERAPEUTICS

NKTR
Real-time Estimate Quote. Real-time Estimate  - 10/28 01:45:27 pm
15.94USD -3.28%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Nektar Therapeutics specializes in the research and development of drugs for the treatment of cancer, autoimmune diseases and chronic pain. Net sales break down by source of income as follows:
- revenues from licensing and collaboration agreements (91.9%);
- product sales (4.6%);
- royalties (3.5%).
At the end of 2018, the Group had a portfolio of 11 products in clinical development (including 4 in phase III, 3 in phase II and 4 in phase I) and a product in pre-clinical development.
Net sales are distributed geographically as follows: the United States (91.4%) and Europe (8.6%).

Number of employees : 723 people.
Sales per Business
20182019
USD
(in Million)
%USD
(in Million)
%
Novel Drugs 1,193100% 114.62100%
Sales per region
2019
USD
(in Million)
%
Rest of World 87.5276.4%
United States 27.0923.6%
Managers
Name Title
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
Gilbert M. Labrucherie Senior VP, Chief Operating & Financial Officer
Jonathan Zalevsky Chief Research & Development Officer
Roy A. Whitfield Independent Director
R. Scott Greer Independent Director
Jeffrey Robert Ajer Independent Director
Karin Eastham Independent Director
Myriam J. Curet Independent Director
Mark A. Wilson Secretary, Senior Vice President & General Counsel
Shareholders
Name Equities %
Invesco Advisers, Inc. 32,523,001 18.2%
PRIMECAP Management Co. 19,406,599 10.8%
Fidelity Management & Research Co. LLC 18,808,197 10.5%
OppenheimerFunds, Inc. 17,302,891 9.67%
The Vanguard Group, Inc. 16,253,875 9.09%
Wellington Management Co. LLP 15,151,481 8.47%
BlackRock Fund Advisors 5,875,776 3.28%
Maverick Capital Ltd. 5,186,637 2.90%
SSgA Funds Management, Inc. 4,464,647 2.50%
HealthCor Management LP 4,000,000 2.24%
Company contact information
455 Mission Bay Boulevard South
CA 94158 San Francisco, California
États-Unis (les)

Phone : +1 415 482 5300
Fax : +1 415 339 5300
Internet : https://www.nektar.com/
Markets and indexes
- Nasdaq Stock Market
- Nasdaq Global Select Market
- SP 500 /
Stock Exchange Codes
- Reuters Code :  NKTR.O
Sector Biotechnology & Medical Research - NEC
1st jan.Capi. (M$)
NEKTAR THERAPEUTICS-25.74%2 948
LONZA GROUP AG63.59%47 362
SEAGEN INC.72.34%34 263
IQVIA HOLDINGS INC.3.00%30 511
CELLTRION, INC.32.04%28 321
MODERNA, INC.261.30%27 885
IMMUNOMEDICS, INC.315.22%20 324
INCYTE CORPORATION1.18%19 322
HANGZHOU TIGERMED CONSULTING CO.,LTD92.97%15 630
ALNYLAM PHARMACEUTICALS, INC.10.12%14 707
PHARMARON BEIJING CO., LTD.121.25%13 063
PPD, INC.0.00%11 856
QIAGEN N.V.47.93%11 437
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.50.08%11 389
BIO-TECHNE CORPORATION21.27%10 264
ICON PUBLIC LIMITED COMPANY8.80%9 902
GALAPAGOS NV-41.96%8 371
ACADIA PHARMACEUTICALS INC.8.37%7 365
CRISPR THERAPEUTICS AG61.10%6 885
PRA HEALTH SCIENCES, INC.-6.88%6 620
IONIS PHARMACEUTICALS, INC.-22.23%6 563